Heart and Kidney Diseases and Type 2 Diabetes May Be One Ailment
a day ago
- #heart disease
- #CKM syndrome
- #diabetes
- Amy Bies experienced high blood glucose and cholesterol after a car accident in 2007, leading to prescriptions for diabetes and cholesterol management.
- Despite medication, Bies suffered a heart attack in 2013 and was on 12 prescriptions by 2019, causing severe side effects.
- Medical researchers now believe these conditions are interconnected, originating from fat cell dysfunction and leading to a cycle of organ damage.
- The American Heart Association named this interconnected condition Cardio-Kidney-Metabolic (CKM) syndrome in 2023.
- New drugs like GLP-1 receptor agonists (e.g., Wegovy, Ozempic) show promise in treating CKM by targeting underlying biological mechanisms.
- Historical research links high blood sugar, blood pressure, and uric acid, with fat cell dysfunction identified as a key factor in disease pathways.
- Insulin resistance and high glucose levels trigger cascading damage to kidneys, heart, and blood vessels, exacerbating CKM.
- Early diagnosis and integrated care models are critical for managing CKM, but challenges remain in screening and treatment coordination.
- GLP-1 and SGLT2 inhibitor drugs have shown benefits beyond diabetes, improving heart and kidney health in clinical trials.
- Despite progress, CKM syndrome's broad nature requires personalized treatment approaches, as not all patients respond the same way.